Elicera Therapeutics Q3: CARMA study initiated - Redeye
Bildkälla: Stockfoto

Elicera Therapeutics Q3: CARMA study initiated - Redeye

Redeye returns following Elicera's Q3 report and recent news in the company. We largely reiterate our stance and see an exciting news flow ahead, most notably related to the ongoing studies with ELC-301 and ELC-100.

Redeye returns following Elicera's Q3 report and recent news in the company. We largely reiterate our stance and see an exciting news flow ahead, most notably related to the ongoing studies with ELC-301 and ELC-100.
Börsvärldens nyhetsbrev
ANNONSER